End-of-day quote
Shenzhen S.E.
23:00:00 16/05/2024 BST
|
5-day change
|
1st Jan Change
|
2.69
CNY
|
+0.37%
|
|
-9.12%
|
-17.74%
|
Fiscal Period: December |
2018
|
2019
|
2020
|
2021
|
2022
|
2023
|
---|
Capitalization
1 |
20,435
|
13,950
|
9,825
|
9,027
|
8,229
|
7,046
|
Enterprise Value (EV)
1 |
18,538
|
10,377
|
6,311
|
6,547
|
5,239
|
4,257
|
P/E ratio
|
22.1
x
|
41.4
x
|
34.6
x
|
-158
x
|
-175
x
|
85.6
x
|
Yield
|
-
|
-
|
4.74%
|
-
|
-
|
-
|
Capitalization / Revenue
|
6.21
x
|
7.86
x
|
10.2
x
|
12.3
x
|
14.4
x
|
14.1
x
|
EV / Revenue
|
5.63
x
|
5.85
x
|
6.55
x
|
8.91
x
|
9.18
x
|
8.55
x
|
EV / EBITDA
|
17.2
x
|
29.1
x
|
20.9
x
|
51.4
x
|
-81.5
x
|
173
x
|
EV / FCF
|
251
x
|
5.97
x
|
16.9
x
|
177
x
|
38.2
x
|
-33.2
x
|
FCF Yield
|
0.4%
|
16.8%
|
5.93%
|
0.57%
|
2.62%
|
-3.01%
|
Price to Book
|
3.86
x
|
2.49
x
|
1.67
x
|
0.7
x
|
1.55
x
|
1.35
x
|
Nbr of stocks (in thousands)
|
2,226,031
|
2,217,870
|
2,217,870
|
2,217,870
|
2,218,178
|
2,154,623
|
Reference price
2 |
9.180
|
6.290
|
4.430
|
4.070
|
3.710
|
3.270
|
Announcement Date
|
26/04/19
|
28/04/20
|
28/04/21
|
26/04/22
|
27/04/23
|
11/04/24
|
Fiscal Period: December |
2018
|
2019
|
2020
|
2021
|
2022
|
2023
|
---|
Net sales
1 |
3,291
|
1,775
|
962.9
|
734.5
|
570.9
|
498.1
|
EBITDA
1 |
1,075
|
357.2
|
302.1
|
127.4
|
-64.27
|
24.61
|
EBIT
1 |
1,030
|
305.2
|
234
|
49.77
|
-153.1
|
-55.69
|
Operating Margin
|
31.31%
|
17.2%
|
24.3%
|
6.78%
|
-26.82%
|
-11.18%
|
Earnings before Tax (EBT)
1 |
1,053
|
387.8
|
349.3
|
-37.11
|
-121.1
|
81.84
|
Net income
1 |
930.5
|
336.9
|
284.5
|
-57.58
|
-46.91
|
83.31
|
Net margin
|
28.28%
|
18.98%
|
29.55%
|
-7.84%
|
-8.22%
|
16.73%
|
EPS
2 |
0.4162
|
0.1519
|
0.1282
|
-0.0257
|
-0.0212
|
0.0382
|
Free Cash Flow
1 |
73.84
|
1,739
|
373.9
|
37.09
|
137.2
|
-128.2
|
FCF margin
|
2.24%
|
97.99%
|
38.83%
|
5.05%
|
24.03%
|
-25.74%
|
FCF Conversion (EBITDA)
|
6.87%
|
486.99%
|
123.76%
|
29.11%
|
-
|
-
|
FCF Conversion (Net income)
|
7.94%
|
516.23%
|
131.41%
|
-
|
-
|
-
|
Dividend per Share
|
-
|
-
|
0.2100
|
-
|
-
|
-
|
Announcement Date
|
26/04/19
|
28/04/20
|
28/04/21
|
26/04/22
|
27/04/23
|
11/04/24
|
Fiscal Period: December |
2022 Q1
|
---|
Net sales
|
-
|
EBITDA
|
-
|
EBIT
|
-
|
Operating Margin
|
-
|
Earnings before Tax (EBT)
|
-
|
Net income
1 |
30.45
|
Net margin
|
-
|
EPS
2 |
0.0136
|
Dividend per Share
|
-
|
Announcement Date
|
29/04/22
|
Fiscal Period: December |
2018
|
2019
|
2020
|
2021
|
2022
|
2023
|
---|
Net Debt
1 |
-
|
-
|
-
|
-
|
-
|
-
|
Net Cash position
1 |
1,897
|
3,574
|
3,514
|
2,480
|
2,990
|
2,789
|
Leverage (Debt/EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
Free Cash Flow
1 |
73.8
|
1,739
|
374
|
37.1
|
137
|
-128
|
ROE (net income / shareholders' equity)
|
18.9%
|
6.16%
|
4.73%
|
-1.68%
|
-2.85%
|
1.03%
|
ROA (Net income/ Total Assets)
|
11.6%
|
3.22%
|
2.37%
|
0.51%
|
-1.67%
|
-0.63%
|
Assets
1 |
7,992
|
10,464
|
11,994
|
-11,273
|
2,807
|
-13,233
|
Book Value Per Share
2 |
2.380
|
2.530
|
2.650
|
5.830
|
2.390
|
2.420
|
Cash Flow per Share
2 |
0.6500
|
0.6700
|
1.090
|
1.600
|
1.170
|
1.290
|
Capex
1 |
68.6
|
65.1
|
110
|
127
|
67.6
|
160
|
Capex / Sales
|
2.08%
|
3.67%
|
11.45%
|
17.28%
|
11.83%
|
32.07%
|
Announcement Date
|
26/04/19
|
28/04/20
|
28/04/21
|
26/04/22
|
27/04/23
|
11/04/24
|
|
1st Jan change
|
Capi.
|
---|
| -17.74% | 804M | | +32.09% | 694B | | +29.39% | 593B | | -1.34% | 371B | | +20.34% | 331B | | +7.39% | 290B | | +14.25% | 239B | | -3.03% | 209B | | +10.02% | 209B | | +8.49% | 169B |
Other Pharmaceuticals
|